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	 A	selective,	sensitive,	and	rapid	liquid	chromatography‐electro	spray	ionization	tandem	mass
spectrometry	method	 has	 been	 developed	 and	 subsequently	 validated	 for	 the	 simultaneous
determination	 of	 Moexipril	 (MOX),	 and	 its	 active	 metabolite	 Moexiprilat	 (MOXT)	 in	 spiked
human	 plasma,	 using	 Benazepril	 (BENZ)	 as	 an	 internal	 standard	 (IS).	 Various	modes	were
tried	and	the	Multiple	Reaction	Monitoring	(MRM)	mode	was	found	the	most	suitable	one.	The
two	 analytes	 and	 Benazepril	 (IS)	 were	 extracted	 from	 human	 plasma	 by	 simple	 protein
precipitation	using	acetonitrile	as	the	precipitating	solvent.	The	stationary	phase	used	was	a
C18	Sunfire	column	while	water	and	acetonitrile	at	0.1%	formic	acid	(30:70,	v:v)	was	used	as	a
mobile	phase.	The	flow	rate	used	was	0.8	mL/min.	Food	and	Drug	Administration	guidelines
were	followed	for	the	method	validation.	The	linearity	range	was	found	to	be	0.5‐100	ng/mL
for	MOX	and	5‐200	ng/mL	for	MOXT	and	the	correlation	coefficient	was	more	than	0.9980	for
each	analyte.	Results	for	accuracy	and	precision	showed	satisfactory	results.	Also	the	method
was	compared	with	reported	HPLC	method	and	no	significant	difference	was	found.	
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1.	Introduction	
	
Moexipril	 (3S)‐2‐[(2S)‐2‐[[(1S)‐1‐(ethoxycarbonyl)‐3‐
phenylpropyl]amino]‐1‐oxopropyl]‐1,	 2,	 3,	 4‐tetrahydro‐6,	 7‐
dimethoxy‐3‐isoquinolinecarboxylic	acid	[1]	is	an	antihyperten‐
sive	drug,	which	belongs	to	the	group	of	angiotensin	convertase	
inhibitors.	 Moexipril	 hydrochloride	 is	 a	 long‐acting	 non‐
sulfhydryl	 angiotensin‐converting	 enzyme	 (ACE)	 inhibitor,	
developed	 for	 the	 treatment	 of	 hypertension	 and	 congestive	
heart	 failure.	 Moexipril	 is	 a	 pro‐drug	 of	 moexiprilat,	 which	
inhibits	ACE	in	humans	and	animals.	In	biological	systems	it	is	
rapidly	 de‐esterified	 by	 esterases,	 resulting	 in	 its	 active	
metabolite	moexiprilat	[2,3].	
It	 is	 reported	 that	 MOX	 was	 identified	 by	 HPLC	 [4‐6],	
spectrophotometry	 [7,8],	 gas	 chromatography	 mass	 spectro‐
metry	 [9],	 and	 liquid	 chromatography	 tandem	 mass	 spectro‐
metry	 [10,11].	 In	 2006,	 Koti,	 J.	 et	 al.	 developed	 a	 LC‐MASS	
spectrometry	method	just	to	monitor	the	metabolism	of	MOX	to	
MOXT	[10].	Also,	 in	2012,	Karra	et	al.	developed	a	method	for	
determination	 of	MOX	by	LC‐Tandem	mass	 spectrometry.	But	
MOXT,	which	is	the	active	metabolite	was	not	determined	[11].	
MOX	is	only	a	pro‐drug,	which	is	converted	inside	the	body	to	
MOXT,	the	active	form.	
There	 is	no	report	of	 liquid	chromatography‐tandem	mass	
spectrometry	studies	 for	simultaneous	estimation	of	MOX	and	
its	active	metabolite	MOXT	in	human	plasma.	
This	 manuscript	 presents	 for	 the	 first	 time	 the	 develop‐
ment	 and	 validation	 of	 a	 sensitive,	 selective	 and	 specific	 LC‐
MS/MS	method	in	multiple	reactions	monitoring	(MRM)	mode	
for	the	quantification	of	MOX	and	MOXT	in	human	plasma	using	
Benazepril	(BENZ)	as	an	internal	standard	(IS).	
	
2.	Experimental	
	
2.1.	Materials	and	reagents	
	
MOX	 and	 BENZ	 were	 kindly	 supplied	 from	 National	
Organization	 for	 Drug	 Control	 and	 Research	 (NODCAR,	 Cairo,	
Egypt).	 The	 purity	 of	 the	 standards	 was	 higher	 than	 99%.	
Where	MOXT	was	prepared	by	the	basic	hydrolysis	of	MOX	as	
will	be	explained	in	section	2.5.1.	Structures	of	the	compounds	
are	shown	in	Figure	1.		
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Figure	1.	Chemical	Structure	of	(a)	Moexipril,	(b)	Moexiprilat,	and	(c)	Benazepril.	
	
	
HPLC‐grade	 acetonitrile	 (Sigma‐Aldrich),	 and	 ultrapure	
water	 prepared	 by	 a	 Millipore	 Milli‐Q	 purification	 system	
(Millipore	Corp.	Bedford,	MA,	USA)	were	used	as	mobile	phase	
of	 the	 HPLC‐MS‐MS.	 Other	 reagents	 were	 of	 analytical‐grade.	
Drug‐free	 human	 plasma	 was	 obtained	 from	 The	 Holding	
Company	for	Biological	Products	&	Vaccines	(VACSERA,	Cairo,	
Egypt).	Plasma	was	stored	below	‐40	°C	until	used	for	analysis.	
	
2.2.	Instruments	
	
Analysis	 was	 performed	 on	 a	 chromatographic	 system	
Shimadzu	LC‐20	AT	Series	HPLC	system	(Japan)	equipped	with	
LC‐20	 AT	 HPLC	 pump,	 Shimadzu	 series	 DGU‐20A5	 Degasser	
and	 a	 Shimadzu	 SIL‐20A	 auto	 sampler.	 A	 chromatographic	
separation	was	achieved	by	a	Sunfire	C18	column	(50×4.6	mm,	
5	 µm,	 Waters,	 USA)	 and	 a	 mixture	 of	 0.1%	 formic	 acid:	
acetonitrile	(30:70,	v:v)	as	a	mobile	phase.	The	isocratic	mobile	
phase,	 was	 filtered	 through	 a	 0.45	 µm	 membrane	 filter	
(Millipore,	USA),	then	sent	to	sonicator	for	5	min.	The	flow	rate	
used	was	0.8	mL/min.	
The	 Multiple	 Reaction	 Monitoring	 (MRM)	 in	 positive	 ion	
mode	was	used	 for	quantitative	determination	of	 the	analytes	
and	 IS	using	a	MDS	Sciex	 (Foster	City,	CA,	USA)	API‐3200	LC‐
MS/MS	triple	quadrupole	mass	spectrometer,	equipped	with	a	
Turbo	ion	spray	 interface	at	350	°C.	The	common	parameters,	
collision	activated	dissociation	gas	(CAD),	nebulizer	gas	(GS1),	
and	heater	gas	(GS2)	were	set	at	5,	30	and	40	psi,	respectively.	
The	 compound	 parameters,	 collision	 exit	 potential	 (CXP),	
collision	 energy	 (CE),	 and	 declustering	 potential	 (DP)	 for	 the	
analytes	 and	 IS	 were	 set	 at	 12,	 31,	 and	 56	 V,	 respectively.	
Simultaneous	quantitative	determination	of	MOX,	MOXT,	and	IS	
was	 done	 by	 monitoring	 the	 parent/daughter	 ions	 at	 m/z	
499.4/234.2,	 471/206,	 and	 425.2/351.2,	 respectively.	 Data	
acquisition	was	made	with	Analyst	software	(version	1.4.2).	
	
2.3.	Preparation	of	standard	solutions,	calibration	
standards	and	quality	control	samples	
	
Standard	solutions	of	MOX,	MOXT,	and	internal	standard	(1	
mg/mL)	 were	 prepared	 in	 acetonitrile.	 Further	 dilution	 was	
done	for	the	preparation	of	standard	working	solution	of	MOX,	
MOXT,	and	internal	standard	(1	µg/mL).	The	standard	working	
solutions	were	stored	at	4	°C	until	used	for	analysis,	where	they	
were	equilibrated	to	room	temperature.	Different	aliquots	from	
the	 standard	 working	 solutions	 were	 used	 for	 spiking	 blank	
human	 plasma	 to	 prepare	 calibration	 standards	 and	 quality	
control	 samples.	 Six	 different	 concentrations	 of	MOX	 (0.5‐100	
ng/mL)	and	MOXT	(5‐200	ng/mL)	were	used	as	the	calibration	
samples.	 Quality	 control	 samples	 used	 were:	 0.5	 (LLOQ),	 15	
(LQC),	50	(MQC),	100	ng/mL	(HQC)	for	MOX,	and	5	(LLOQ),	30	
(LQC),	100	(MQC),	200	ng/mL	(HQC)	for	MOXT.		
	
2.4.	Simple	protein	precipitation	
	
A	 simple	 protein	 precipitation	 was	 done	 for	 extracting	
MOX,	 its	 active	metabolite	MOXT,	 and	BENZ	 (IS)	 from	human	
plasma.	BENZ	(IS)	solution	(25	µL	of	1000	ng/mL)	was	added	
to	500	µL	plasma.	Acetonitrile	(3	mL)	was	added	to	precipitate	
plasma	proteins,	and	then	the	samples	were	vortexed	for	1	min.	
The	 Centrifugation	 was	 done	 at	 10,000	 rpm	 for	 10	 min.	 The	
clear	 supernatant	 was	 transferred	 to	 a	 dry	 test	 tube	 and	
evaporated	to	dryness	under	a	gentle	stream	of	nitrogen	gas	at	
40	 °C,	 and	 then	 the	 residue	was	 reconstituted	with	100	µL	of	
the	mobile	 phase,	 where	 only	 25	 µL	was	 injected	 for	 the	 LC‐
tandem	mass	analysis.		
	
2.5.	Procedures	
	
2.5.1.	Stability	of	MOX	
	
MOX	 was	 subjected	 to	 basic	 degradation.	 Standard	 MOX	
powder	 (100	mg)	was	weighed	 transferred	 to	 a	 conical	 flask.	
Then,	0.1	N	NaOH	was	added	on	the	volumetric	flask.	Then	the	
flask	was	refluxed	for	0.5	hour.	After	the	reflux,	the	conical	flask	
was	neutralized	against	0.1	N	HCl,	 then	completed	 to	100	mL	
by	 distilled	 water.	 The	 complete	 degradation	 was	 confirmed	
using	HPLC	and	mass	spectrometry.	
	
2.5.2.	For	bulk	powder		
	
Aliquot	 volumes	 from	 the	 standard	 working	 solutions	 of	
MOX	 and	 MOXT	 were	 accurately	 transferred	 to	 10	 mL	 volu‐
metric	flasks	to	which	500	µL	of	IS	was	added	to	provide	final	
concentrations	 of	 0.5‐100	 ng/mL	 for	 MOX,	 and	 5‐200	 ng/mL	
for	 MOXT.	 The	 volume	 was	 completed	 to	 the	 volume	 by	 the	
mobile	phase.	 25	µL	of	 each	 concentration	was	 injected	 three	
times	and	following	the	chromatographic	conditions.	
	
2.5.3.	For	extraction	from	human	plasma	
	
Aliquot	 volumes	 from	 the	 standard	 working	 solutions	 of	
MOX	and	MOXT	were	added	on	500	µL	human	plasma,	then	25	
µL	 IS	was	 added	 on	 each	 concentration.	 Then,	 3	mL	 of	 aceto‐
nitrile	was	 added,	 the	 samples	were	mixed	 on	 a	 vortex	 for	 1	
min,	followed	by	centrifugation	for	10	min	at	10,000	rpm.	The	
clear	supernatant	was	transferred	to	a	clean	tube	and	evapora‐
ted	to	dryness	under	a	gentle	stream	of	nitrogen	gas	at	40	°C.	
The	residue	was	reconstituted	with	100	µL	mobile	phase,	and	
25	µL	was	injected	for	LC‐tandem	mass	analysis.		
	
2.6.	Method	validation	
	
The	validation	of	the	proposed	method	was	done	as	per	the	
FDA	guidelines.	
	
2.6.1.	Selectivity	
	
Blank	human	plasma	from	six	different	sources	were	tested	
for	 any	 interference	 of	 endogenous	 plasma	 constituents	 with	
the	analytes	and	the	IS.	
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2.6.2.	Matrix	effect	
	
It	 is	 the	 effect	 of	 the	 matrix	 which	 contains	 the	 analysed	
sample	 on	 the	 sample	 determination.	 To	 test	 for	 the	 effect	 of	
the	 studied	 matrix	 on	 the	 quantitative	 determination	 of	 the	
analytes,	extraction	was	done	to	blank	human	plasma	samples	
as	explained	earlier,	and	after	the	extraction	step,	 the	samples	
were	spiked	with	three	different	quality	control	levels	with	the	
IS	 in	 triplicates.	 Then	 the	 samples	 were	 sent	 for	 analysis	 to	
obtain	the	peak	areas.	The	peak	areas	obtained	were	compared	
with	 those	 obtained	 from	 standard	 solutions,	 where	 matrix	
effect	 is	 the	 peak	 area	 ratio.	 Matrix	 effect	 is	 usually	 done	 to	
ensure	the	precision	and	repeatability	of	the	method.	
	
2.6.3.	Recovery		
	
Calculation	 of	 the	 recovery	 %	 is	 done	 to	 test	 for	 the	
extraction	 efficiency	 of	 the	method.	 The	 extraction	 procedure	
was	done	 as	mentioned	 above	 for	 the	 spiked	plasma	 samples	
and	 the	 peak	 areas	 were	 calculated.	 Then	 the	 peak	 areas	 of	
samples	 spiked	 after	 the	 extraction	 step	 was	 calculated.	 The	
ratio	 of	 the	 two	peaks	was	 the	 recovery	%.	 This	was	 done	 at	
three	quality	control	levels	in	triplicates.	
	
2.6.4.	Calibration	curves	
	
Samples	used	for	calibration	consist	of	six	concentrations	of	
MOX	 (0.5‐100	 ng/mL)	 and	 MOXT	 (5‐200	 ng/mL).	 Each	
concentration	was	injected	three	times.	The	relative	peak	area	
of	 each	 analyte	 was	 recorded	 against	 its	 concentration,	 the	
linearity	curves	were	constructed	and	the	regression	equations	
computed.	
	
2.6.5.	Precision	and	accuracy	
	
Three	 different	 QC	 levels	 of	 each	 analyte	 were	 analysed	
three	times	 intra‐daily	using	the	proposed	methods	under	the	
same	 experimental	 conditions	 to	 estimate	 precision	 and	
accuracy.	 The	 previous	 procedures	 were	 repeated	 inter‐daily	
on	 three	 different	 days	 for	 the	 analysis	 of	 the	 three	 chosen	
concentrations	 to	 calculate	 the	 inter‐assay	 precision.	 The	
relative	 standard	 deviations	 were	 calculated.	 The	 criteria	 for	
acceptability	 of	 data	 were	 accuracy	 within	 ±15%	 from	 the	
nominal	 values	 and	 a	 precision	 of	 within	 ±15%	 relative	
standard	 deviation	 (RSD),	 but	 that	 of	 LQC	 is	 not	 supposed	 to	
exceed	±20%	(US	DHHS,	FDA,	CDER,	2001)	[12].	
	
2.6.6.	Stability	
	
2.6.6.1.	Short‐term	stability	
	
To	 test	 for	 the	 short	 term	 stability	 of	 the	 analytes,	 three	
quality	 control	 levels	 were	 left	 for	 8	 hours	 on	 bench	 top	 at	
room	 temperature	 (bench‐top	 stability).	 This	 was	 done	 in	
triplicates.	
	
2.6.6.2.	Freeze	and	thaw	stability	
	
Three	 freeze	 and	 thaw	 cycles	were	 applied	 to	 test	 for	 the	
analytes’	stability.	The	general	procedure	mentioned	above	was	
applied	 for	 the	 analysis.	 The	 same	 criteria	 of	 data	 acceptance	
mentioned	under	precision	apply	here.	
	
2.6.6.3.	Stock	solution	stability	
	
The	 stability	 of	 MOX,	 MOXT,	 and	 I.S	 stock	 solutions	 was	
performed	 by	 comparison	 of	 results	 from	 a	 solution	 kept	 for	
about	 60	 days	 at	 4	 °C	 and	 from	 a	 solution	 that	 was	 extem‐
poraneously	 prepared.	 For	 this	 purpose,	 three	 replicates	 of	
each	 analyte	 were	 prepared	 from	 each	 stock	 solution	 and	
injected	in	the	LC‐MS/MS	system.	The	same	test	was	performed	
with	 the	 stock	 solutions	 of	 I.S.	 Results	 were	 compared	 to	
freshly	prepared	solutions	at	corresponding	concentration.	The	
samples	qualified	the	test	if	the	deviation	was	within	±15%.	
	
3.	Results	and	discussion	
	
3.1.	Method	development	
	
3.1.1.	Mass	spectrometry	
	
Both	 positive	 and	 negative	 ion	 modes	 were	 tried	 for	 the	
simultaneous	 determination	 of	 the	mixture	 by	using	 only	 one	
internal	 standard.	The	Positive	 ion	mode	was	 found	 to	be	 the	
most	 suitable	 for	 the	 LC‐tandem	 mass	 multiple	 reaction	
monitoring	(MRM)	analyses.	Parent	 ion	of	each	analyte	and	 IS	
[M+H]+	 in	 the	 first	 MS	 was	 used	 to	 give	 the	 most	 intense	
product	ion	peak	in	MS3	where	it	was	used	for	the	quantitative	
measurement.	
The	 parent	 ion	 of	 the	 protonated	 MOX	 and	 MOXT	 (m/z,	
499.4)	 and	 (m/z,	 471)	 formed	 the	most	 intense	 daughter	 ion	
peak	at	234.2	and	m/z	206,	respectively.	Also,	the	protonated	IS	
(BENZ,	m/z	425.2)	formed	the	most	intense	daughter	ion	peak	
at	m/z	351.2,	Figure	2.	
	
3.1.2.	Chromatographic	conditions	
	
Different	 ratios	 of	 acetonitrile	 and	 buffer	 were	 tested	 for	
optimum	 resolution	 in	 a	 reasonable	 run	 time	 and	 acceptable	
peak	 shape.	 The	 most	 satisfactory	 mobile	 phase	 ratio	 was	
found	to	be	0.1%	formic	acid	and	acetonitrile	(30:70,	v:v).	Two	
types	of	stationary	phases	C8	and	C18	were	investigated	for	the	
optimum	 resolution	 of	 the	 analytes	 peaks,	 however	 the	more	
hydrophobic	 sunfire	 C18	 was	 found	 to	 be	 more	 superior	 in	
separating	analytes	peaks	in	a	reasonable	run	time.	
	
3.1.3.	Simple	protein	precipitation	
	
Simple	 protein	 precipitation	 was	 used	 to	 obtain	 samples	
free	 from	 endogenous	 interferents,	 which	 are	 essential	 for	
increasing	 recovery	 and	 minimizing	 matrix	 effects	 in	 LC‐
tandem	 mass	 spectrometry.	 Different	 precipitating	 solvents,	
like	 methanol,	 and	 acetonitrile	 were	 tried	 and	 tested	 for	
removing	 interferents	 and	 obtaining	 clean	 plasma	 samples	
leading	to	acceptable	matrix	effect	and	recoveries.	Acetonitrile	
proved	 to	 be	 the	most	 suitable,	 so	 it	was	 used	 in	 the	 protein	
precipitation	step.	
	
3.1.4.	Selection	of	internal	standard	
	
Internal	 standard	 (IS)	 is	 used	 to	 compensate	 for	 the	
analytes	 during	 any	 step	 of	 the	 analysis.	 Also,	 matrix	 effect	
could	be	minimized	by	choosing	suitable	IS.	Several	compounds	
were	investigated,	such	as	torasemid,	gliclazide,	and	BENZ,	and	
finally	BENZ	was	found	to	be	the	most	suitable	IS.		
	
3.2.	Method	validation	
	
3.2.1.	Selectivity	
	
To	 test	 for	 the	 method	 selectivity,	 blank	 plasma	 samples	
from	 six	 different	 sources	 were	 analyzed	 to	 be	 sure	 that	 the	
endogenous	 plasma	 constituents	 show	 no	 interference	 at	 the	
peak	 region	 of	 the	 studied	 analytes	 and	 the	 IS.	 The	 proposed	
method	showed	no	interference	at	the	m/z	ratio	of	the	analytes	
and	IS,	Figure	3‐5.	
	
3.2.2.	Lower	limit	of	the	quantitation	(LLOQ)	
	
The	LLOQ	was	defined	as	 the	 lowest	 concentration	on	 the	
calibration	curves	with	acceptable	precision	and	recovery.		
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Table	1.	The	recovery	and	matrix	effect	of	moexipril,	moexiprilat,	and	IS	(n	=	3).	
Analyte	
	
C	(ng/mL)	
		
Recovery	(	%	) Matrix	effect	(%)	
x±SD RSD	% x±SD 		 RSD	%
Moexipril	 15	 84.6±3.87 4.57 99.7±2.45 	 2.46
50	 83.7±5.41 6.46 98.3±1.48 	 1.50
180	 84.6±5.23 6.18 98.7±1.62 	 1.64
Moexiprilat	 3	 86.5±4.84	 	 5.60	 	 98.9±2.16	 	 2.18	
30	 85.1±8.64	 	 10.15	 	 99.5±3.12	 	 3.14	
100	 85.5±2.47 2.89 99.4±1.57 	 1.58
IS	 10	 87.3±4.57	 		 5.23	 		 99.7±2.47	 		 2.48	
	
(a)	
(b)	
	(c)	
Figure	2.	MS	spectra	for	(a)	Moexipril,	(b)	Moexiprilat,	and	(c)	Benazepril.	
	
	
The	 analyte	 response	 at	 the	 LLOQ	 should	 be	 at	 least	 five	
times	 the	 response	 of	 blank	 baseline.	 To	 test	 for	 LLOQ	 of	 the	
proposed	 method,	 three	 replicates	 of	 the	 spiked	 plasma	
samples	were	analyzed	at	concentrations	of	0.5	and	5.0	ng/mL	
for	MOX	 and	MOXT,	 respectively.	 The	 precision	 and	 accuracy	
were	found	to	be	5.09	and	102%	for	MOX;	0.97	and	104%	for	
MOXT,	respectively.	
	
3.2.3.	Recovery	and	matrix	effect	
	
Different	 precipitating	 solvents	were	 tried	 to	 obtain	 clean	
samples,	 minimize	 matrix	 effect,	 and	 increase	 recovery	 %.	
Acetonitrile	proved	to	be	 the	most	suitable	one	 for	extraction.	
The	recoveries	and	matrix	effects	of	MOX,	MOXT,	and	BENZ	(IS)	
are	shown	in	Table	1.	Where	three	quality	control	 levels	were	
tested	in	triplicates.	
	
		
3.2.4.	Linearity	
	
The	 two	 analytes	 showed	 linear	 response	 where	 the	
correlation	 coefficients	 (r2)	were	 all	 >	 0.998.	 The	 equation	 of	
each	calibration	curve	was:	y	=	0.0068X	‐	0.0072	(r2	=	0.9981,	n	
=	 3)	 for	MOX	 and	 y	 =	 0.6098x‐0.135	 (r2	 =	 0.9988,	 n	 =	 3)	 for	
MOXT.	
	
3.2.5.	Precision	and	accuracy		
	
Intra‐	and	inter‐day	precision	and	accuracy	data	for	plasma	
samples	 of	 the	 two	 analytes	 are	 shown	 in	 Table	 2.	 The	 data	
showed	acceptable	results	for	both	precision	and	accuracy.	
	
3.2.6.	Stability	studies	
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Table	2.	The	intra‐day	and	inter‐day	precisions	and	accuracy	of	moexipril	and	moexiprilat	in	plasma	(n	=	3).	
Analyte	 C	(ng/mL)	
		
Intra‐day	 		 Inter‐day	
x±SD	 Accuracy	% RSD	% x±SD Accuracy	%	 RSD	%
Moexipril	 15	 14.56±1.41	 97.1 9.68 14.78±2.14 98.5	 14.48
50	 51.23±0.57	 102.5 1.11 48.89±1.87 97.8	 3.82
100	 98.63±1.37	 98.6 1.39 98.32±0.25 98.3	 0.25
Moexiprilat	 5	 4.870±0.41	 97.4 8.42 4.840±0.23 96.8	 4.75
30	 29.47±1.25	 98.2	 4.24	 	 31.26±0.54	 104.2	 1.73	
	 100	 99.54±0.64	 99.5	 0.64	 		 99.78±2.54	 99.8	 2.55	
	
	
Table	3.	Stability	data	of	moexipril	and	moexiprilat	in	human	plasma	at	various	conditions	(n	=	3).	
Analyte	 C	(ng/mL)	 		 Bench	top	(8	h) Three	freeze‐thaw	
Moexipril	 15	 x±SD	 14.98±0.43	 14.21±3.14	
	 Accuracy	% 99.87 94.73	
50	 x±SD 50.56±0.48 48.87±2.87	
	 Accuracy	% 101.12 97.74	
100	 x±SD 100.69±1.24 101.24±3.04	
	 Accuracy	% 100.69 101.24	
Moexiprilat	 5	 x±SD	 5.08±1.12	 5.19±2.47	
	 Accuracy	% 101.60 103.80	
30	 x±SD 30.87±0.76 31.65±2.41	
	 Accuracy	% 102.90 105.50	
100	 x±SD 99.78±1.42 98.78±0.58	
	 		 Accuracy	% 99.78 98.78	
	
	
	(a)	
	
(b)	
	
(c)	
	
Figure	 3.	Blank	 human	 plasma	 showing	 no	 interference,	 a)	 Moexipril,	 (b)	
Moexiprilat,	and	(c)	Benazepril.	
	
3.2.6.1.	Short	term	stability	
	
Bench	Top	stability	was	checked	for	each	analyte	by	leaving	
the	 spiked	 human	 plasma	 for	 8	 hours	 on	 bench‐top.	 The	
concentration	 of	 the	 analytes	never	 falls	 outside	 the	 accepted	
range	as	seen	in	Table	3.		
		
	(a)	
(b)
(c)	
	
Figure	 4.	 MRM	 chromatograms	 of	 moexipril	 (a),	 moexiprilat	 (b),	 and	
benazepril	(c).	
	
3.2.6.2.	Freeze	and	thaw	stability	
	
The	 stability	 of	 the	 analytes	 in	 human	 plasma	 was	
investigated	 under	 the	 conditions	 recommended	 by	 the	 FDA	
[12].	 So,	 freeze‐thaw	stability	was	 assessed	with	 three	 sets	 of	
stability	 control	 samples	 after	 three	 freeze‐thaw	 cycles	 and	
during	storage	at	‐80	°C	up	to	30	days	(Table	3).		
Elaziz	et	al.	/	European	Journal	of	Chemistry	5	(4)	(2014)	662‐667	 667	
 
	
Table	4.	Statistical	comparison	for	the	results	obtained	by	the	proposed	method	and	the	reported	method	[4]	for	the	analysis	of	Moexipril	in	bulk	powder.	
Method	 Drug	 Mean	 S.D.	 RSD%	 N	 Variance	 Student's	t	test	(2.23)	a	 F	test	(5.05)	a	
LC/MS	 MOX	 99.32	 2.77 2.788 6 7.672 0.258 1.681
Reported	method	[1]	b	 MOX	 99.24	 2.12 2.136 6 4.562 		
a	The	values	in	parenthesis	are	the	corresponding	theoretical	values	of	t	and	F	at	p	=	0.05.	
b	Separation	was	achieved	on	Luna	C18	column	(250×4.6	mm	I.D.,	5	um,	acetonitrile‐20	mM	phosphate	buffer	(pH	=	4.0)	(50:50,	v:v)	at	a	flow	rate	of	1	mL/min,	
and	UV	detection	at	212	nm.	
	
(a)	
	
(b)	
	
(c)	
	
Figure	 5.	 MRM	 chromatograms	 of	 moexipril	 (a),	 moexiprilat	 (b),	 and	
benazepril	(c)	in	spiked	human	plasma.	
	
	
3.2.6.3.	Stock	solution	stability	
	
The	stability	of	the	MOX,	MOXT,	and	I.S.	stock	solutions	was	
performed	 by	 comparison	 of	 results	 from	 a	 solution	 kept	 for	
about	60	days	at	4	°C	and	from	a	solution	that	was	extempora‐
neously	 prepared.	 For	 this	 purpose,	 three	 replicates	 of	 each	
analyte	were	prepared	from	each	stock	solution	and	injected	in	
the	LC‐MS/MS	system.	The	same	test	was	performed	with	 the	
stock	 solutions	 of	 I.S.	 Results	 were	 compared	 to	 freshly	
prepared	solutions	at	corresponding	concentration	as	shown	in	
Table	3.	
	
4.	Statistical	analysis	
	
Results	 obtained	 by	 the	 proposed	 method	 for	 the	 deter‐
mination	 of	 pure	 samples	 of	 MOX	 and	MOXT	 are	 statistically	
compared	 to	 those	 obtained	 by	 the	 reported	 methods4.	 The	
calculated	 t	 and	 F	 values	 were	 found	 to	 be	 less	 than	 their	
corresponding	 theoretical	 ones	 confirming	 good	 accuracy	 and	
excellent	precision	(Table	4).	
5.	Conclusions	
	
In	 the	 present	 study,	 both	 MOX	 and	 its	 active	 metabolite	
MOXT	 were	 determined	 in	 spiked	 human	 plasma	 by	 LC‐
Tandem	mass	spectrometry	method	using	one	IS.	The	method	
showed	 satisfactory	 precision	 and	 accuracy	 results.	 The	 run	
time	of	the	developed	method	is	too	short,	so	it	can	be	used	in	
bioequivalence	studies	to	test	maximum	number	of	samples	in	
a	short	time.	
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